23.03

1.12% -0.26

After Hours: 23.03

Vor Biopharma Inc (VOR)

Overview News Price History Option Chain Financials Discussions Forecast

Vor Biopharma Inc stock is traded at $23.03, with a volume of 417.54K. It is down -1.12% in the last 24 hours and up +24.49% over the past month. Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Previous Close:

$23.29

Open:

$23.33

24h Volume:

417.54K

Relative Volume:

0.36

Market Cap:

$1.36B

Revenue:

Net Income/Loss:

$-883.08M

P/E Ratio:

-0.0691

EPS:

-333.4782

Net Cash Flow:

$-150.65M

1W Performance:

-2.70%

1M Performance:

+24.49%

6M Performance:

+80.20%

1Y Performance:

-41.84%

1-Day Range:

$22.38

$23.35

1-Week Range:

$21.75

$23.84

52-Week Range:

$6.50

$50.20

Vor Biopharma Inc Stock (VOR) Company Profile

Name

Vor Biopharma Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

617-655-6580

Address

500 BOYLSTON STREET, BOSTON

Employee

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

VOR's Discussions on Twitter

Compare VOR vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VOR Vor Biopharma Inc	23.03	1.32B	0	-883.08M	-150.65M	-333.48
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-30-26	Initiated	Jefferies	Buy
Mar-19-26	Initiated	Wells Fargo	Overweight
Jan-09-26	Initiated	Citigroup	Buy
Dec-17-25	Initiated	TD Cowen	Buy
Dec-09-25	Initiated	JP Morgan	Overweight
Nov-25-25	Resumed	Wedbush	Neutral
Oct-15-25	Upgrade	Robert W. Baird	Neutral → Outperform
Sep-24-25	Upgrade	Stifel	Hold → Buy
Jun-30-25	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-26-22	Initiated	Wedbush	Outperform
Apr-27-22	Initiated	Goldman	Neutral
Dec-17-21	Initiated	H.C. Wainwright	Buy
Dec-03-21	Initiated	Robert W. Baird	Outperform
Dec-02-21	Initiated	Oppenheimer	Outperform
Oct-19-21	Initiated	JMP Securities	Mkt Outperform
Mar-25-21	Initiated	B. Riley Securities	Buy
Mar-03-21	Initiated	Barclays	Overweight
Mar-03-21	Initiated	Evercore ISI	Outperform
Mar-02-21	Initiated	Goldman	Sell
Mar-02-21	Initiated	Stifel	Buy

View All

Vor Biopharma Inc Stock (VOR) Latest News

Aug 15, 2026

Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold - marketbeat.com

Aug 15, 2026

Aug 14, 2026

Vor Biopharma (VOR) sees Venrock-led group report 9.99% ownership stake - Stock Titan

Aug 14, 2026

Vor Biopharma (VOR) sees Frazier Life Sciences entities report under 5% ownership - Stock Titan

Aug 14, 2026

Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright - marketbeat.com

Aug 14, 2026

VOR|Vor Biopharma Inc|Price:23.260|Chg%:+0.920 - TradingKey

Aug 14, 2026

Aug 13, 2026

Verve Capital Limited (VOR) reports 6.3% stake in Vor Biopharma common stock - Stock Titan

Aug 13, 2026

Vor Biopharma FY2030 EPS Forecast Reduced by HC Wainwright - marketbeat.com

Aug 13, 2026

Vor Biopharma (VOR) Stock Looks Reasonable On Earnings Yet Weak On Broader Checks - Sahm

Aug 13, 2026

Aug 12, 2026

VOR BIOPHARMA INC. : WEDBUSH RAISES TARGET PRICE TO $27 FROM $18 - webull.com

Aug 12, 2026

VOR Maintains Rating by Wedbush -- Price Target Raised to $27.00 - GuruFocus

Aug 12, 2026

Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price - marketbeat.com

Aug 12, 2026

Vor Biopharma (NASDAQ:VOR) Trading Down 6.5% on Disappointing Earnings - marketbeat.com

Aug 12, 2026

Wells Fargo Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $30 - Moomoo

Aug 12, 2026

Vor Biopharma (VOR) Reports Improved Cash Position and Reduced L - GuruFocus

Aug 12, 2026

Aug 11, 2026

Vor Biopharma Reports Q2 2026 Financial Results in SEC Form 10-Q Filing - Kalkine Media

Aug 11, 2026

Vor Biopharma Q2 Adj. EPS $(0.80) Misses $(0.70) Estimate - scanx.trade

Aug 11, 2026

Vor Biopharma (NASDAQ:VOR) Posts Earnings Results - marketbeat.com

Aug 11, 2026

Vor Biopharma (VOR) Strengthens Cash Position Amid Unprofitable Operations - GuruFocus

Aug 11, 2026

VOR Stock Update: Telitacicept Advances Amid Mixed Financial Sig - GuruFocus

Aug 11, 2026

Vor Biopharma Shares Drop After Q2 Results - marketscreener.com

Aug 11, 2026

Vor Biopharma Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 11, 2026

Vor Biopharma posts wider-than-expected Q2 loss on increased G&A costs - TradingView

Aug 11, 2026

Earnings Flash (VOR) Vor Biopharma Posts Q2 Net Loss $1.16 a Share, vs. FactSet Est of $0.70 Loss - marketscreener.com

Aug 11, 2026

Vor Biopharma Inc. 2Q 2026: Net loss $(62.8M), EPS $(1.16) — 10-Q Summary - TradingView

Aug 11, 2026

Vor Biopharma (VOR) cuts losses as telitacicept trials advance and cash runway reaches 2029 - Stock Titan

Aug 11, 2026

Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewswire

Aug 11, 2026

Renaissance Technologies LLC Makes New $2.30 Million Investment in Vor Biopharma Inc. $VOR - marketbeat.com

Aug 11, 2026

Aug 09, 2026

Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Analysts - marketbeat.com

Aug 09, 2026

Aug 07, 2026

FMR LLC discloses 12% VOR Biopharma (VOR) stake for Abigail P. Johnson - Stock Titan

Aug 07, 2026

Aug 06, 2026

FMR LLC shows 9.1% Vor Biopharma (VOR) stake in Schedule 13G - Stock Titan

Aug 06, 2026